



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

RECEIVED 09 March 2023
ACCEPTED 09 March 2023
PUBLISHED 21 March 2023

CITATION
Frontiers Production Office (2023) Erratum:
The efficacy of cancer immunotherapies
is compromised by *Helicobacter
pylori* infection.
Front. Immunol. 14:1183107.
doi: 10.3389/fimmu.2023.1183107

COPYRIGHT
© 2023 Frontiers Production Office. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: The efficacy of cancer immunotherapies is compromised by *Helicobacter pylori* infection

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

Helicobacter pylori, cancer, immunotherapy, personalized medicine, gut microbiota, immune checkpoint inhibitors

An erratum on

**The efficacy of cancer immunotherapies is compromised by
Helicobacter pylori infection**

by Oster P, Vaillant L, McMillan B and Velin D (2022) *Front. Immunol.* 13:899161.
doi: 10.3389/fimmu.2022.899161

An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding provided by University of Lausanne”.

The original version of this article has been updated.